Generic Name and Formulations:
Misoprostol 100mcg, 200mcg; tabs.
Indications for CYTOTEC:
Prevention of NSAID-induced gastric ulcers.
Take with food. 200mcg 4 times daily with meals (last dose at bedtime). May reduce dose if not tolerated.
Can cause birth defects, abortion, premature birth or uterine rupture in pregnant women. For women of childbearing potential: negative serum pregnancy test within 2 weeks before starting therapy; begin on 2nd or 3rd day of next menstrual period; maintain contraception during therapy; give oral and written warnings on risks in pregnancy. Cardiovascular disease. Inflammatory bowel disease. Dehydration. Labor & delivery. Nursing mothers.
Avoid magnesium-containing antacids (to reduce diarrhea risk). Concomitant oxytocic agents: not recommended.
Prostaglandin E1 analogue.
Diarrhea, abdominal pain, headache, gynecological effects (eg, spotting, cramps), abortion, premature birth, birth defects, uterine rupture.
Tabs 100mcg—60, 120; 200mcg—60, 100
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|